STOCK TITAN
  1. Home
  2. News
  3. AKBA

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) plans to report Q4 and full year 2023 financial results on March 14, 2024. The company will not host a conference call due to the proximity to the PDUFA target action date for vadadustat, a potential treatment for anemia in patients on dialysis.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., March 11, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024. Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2023-financial-results-302085663.html

SOURCE Akebia Therapeutics, Inc.

Akebia Therapeutics will report its Q4 and full year 2023 financial results on March 14, 2024.

The PDUFA target action date for vadadustat is anticipated to be on March 27, 2024.

Vadadustat is under review by the U.S. FDA as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

Akebia Therapeutics is not hosting a conference call due to the proximity to the PDUFA target action date for vadadustat.
Stock AKBA logo
Akebia Therapeutics Inc.

NASDAQ:AKBA

AKBA Rankings

#3482 Ranked by Market Cap
#30 Ranked by Stock Gains
N/A Ranked by Dividends

AKBA Latest News

Apr 2, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 27, 2024
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Mar 14, 2024
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Mar 1, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 2, 2024
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AKBA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Cambridge

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.